Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity


  • Escudier Marion
  • Cautela Jennifer
  • Malissen Nausicaa
  • Ancedy Yann
  • Orabona Morgane
  • Pinto Johan
  • Monestier Sandrine
  • Grob Jean-Jacques
  • Scemama Ugo
  • Jacquier Alexis
  • Lalevee Nathalie
  • Barraud Jeremie
  • Peyrol Michael
  • Laine Marc
  • Bonello Laurent
  • Paganelli Franck
  • Cohen Ariel
  • Barlesi Fabrice
  • Ederhy Stephane
  • Thuny Franck

document type



Immune checkpoint inhibitors (ICIs) represent a major advance in the treatment of cancer. Although clinical trials reported a low incidence of immune-related cardiovascular adverse events, the number of published life-threatening cases of cardiotoxicity is increasing. In this descriptive observational analysis, we aimed to describe the clinical manifestations, management, and outcomes of patients who developed ICI-related cardiotoxicity.

more information